I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program

Stock Information for I-MAB

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About I-MAB

I-Mab Reports First Quarter 2025 Financial Results and Provides Business Update
I-Mab Announces Givastomig Abstract Accepted for Oral Presentation at ESMO GI 2025
I-Mab Reports Full Year 2024 Financial Results and Provides Business Update
I-Mab to Present at 24th Annual Needham Virtual Healthcare Conference
I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
I-Mab Announces Accelerated Givastomig Phase 1b Study Progress
I-Mab to Participate in Leerink Partners Global Healthcare Conference
I-Mab to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.